Contrasting Effects of Raclopride and SCH 23390 on the Cellular Content of Preproenkephalin A mRNA in Rat Striatum: A Quantitative Non-radioactive In Situ Hybridization Study

Differential gene expression in the striatum of mice with very low expression of the vesicular monoamine transporter type 2 gene

The vesicular monoamine transporter type 2 (VMAT2) packages pre-synaptic monoamines into vesicles. Previously, we generated mice hypomorphic for the VMAT2 gene (Slc18a2), which results in a approximately 95% reduction in VMAT2 protein, disrupted vesicular storage, severe depletion of striatal dopamine and mice with moderate motor behaviour deficits. Dopamine released from mid-brain dopamine neurons acts on post-synaptic type 1 (D1) and 2 (D2) receptors located on striatal medium spiny neurons to initiate a signalling cascade that leads to altered transcription factor activity, gene expression and neuronal activity. We investigated striatal gene expression changes in VMAT2hypo mice by quantitative real-time PCR and in situ hybridisation. Despite unaltered expression of D1 and D2 dopamine receptors, there were dramatic alterations in striatal mRNAs encoding the neuropeptides substance P, dynorphin, enkephalin and cholecystokinin. The promoters of these genes are regulated by a combination of transcription factors that includes cAMP responsive element binding protein-1 (CREB) and c-Fos. Indeed, the changes in peptide mRNAs were associated with elevated expression of Creb1 and c-Fos. These data indicate that striatal dopamine depletion, as a consequence of deficient vesicular storage in this mouse, triggers a complex program of gene expression, consistent with this mouse being an excellent model of Parkinson's disease.

Chemical and anatomical changes in the striatum and substantia nigra following quinolinic acid lesions in the striatum of the rat: a detailed time course of the cellular and GABA(A) receptor changes

The pattern and time-course of cellular, neurochemical and receptor changes in the striatum and substantia nigra were investigated following unilateral quinolinic acid lesions of the striatum in rats. The results showed that in the central region of the striatal lesion there was a major loss of Nissl staining of the small to medium sized cells within 2 h and a substantial loss of neuronal staining within 24 h after lesioning. Immunohistochemical studies showed a total loss of calbindin immunoreactivity, a known marker of GABAergic striatal projection neurons, throughout the full extent of the quinolinic acid lesion within 24 h. Similarly, within 24 h, there was a total loss of somatostatin/neuropeptide Y cells in the centre of the lesion but in the periphery of the lesion these cells remained unaltered at all survival times. Striatal GABA(A) receptors remained unchanged in the lesion for 7 days, and then declined in density over the remainder of the time course. Glial fibrillary acidic protein immunoreactive astrocytes were present in the periphery of the lesion at 7 days, occupied the full extent of the lesion by 4 weeks, and remained elevated for up to 2 months. In the substantia nigra, following placement of a striatal quinolinic acid lesion, there was: a loss of substance P immunoreactivity within 24 h; a marked astrocytosis evident from 1-4 weeks postlesion; and, a major increase in GABA(A) receptors in the substantia nigra which occurred within 2 h postlesion and was sustained for the remainder of the time course (15 months). This study shows that following quinolinic acid lesions of the striatum there is a major loss of calbindin and somatostatin/neuropeptide Y immunoreactive cells in the striatum within 24 h, and a marked increase in GABA(A) receptors in the substantia nigra within 2 h. These findings are similar to the changes in the basal ganglia in Huntington's disease and provide further evidence supporting the use of the quinolinic acid lesioned rat as an animal model of Huntington's disease.

Phenotypic characterization of neurotensin messenger RNA-expressing cells in the neuroleptic-treated rat striatum: a detailed cellular co-expression study

The chemical phenotype of proneurotensin messenger RNA-expressing cells was determined in the acute haloperidol-treated rat striatum using a combination of (35S)-labelled and alkaline phosphatase-labelled oligonucleotides. Cellular sites of proneurotensin messenger RNA expression were visualized simultaneously on tissue sections processed to reveal cellular sites of preproenkephalin A messenger RNA or the dopamine and adenylate cyclase phosphoprotein-32, messenger RNA. The cellular co-expression of preproenkepahlin A (enkephalin) and preprotachykinin (substance P) messenger RNA was also examined within forebrain structures. Cellular sites of enkephalin (substance P) and dopamine and adenylate cyclase phosphoprotein-32 messenger RNAs were visualized using alkaline phosphatase-labelled oligonucleotides whilst sites of substance P and proneurotensin messenger RNA expression were detected using (35S)-labelled oligos. Cellular sites of enkephalin and dopamine and adenylate cyclase phosphoprotein-32 gene expression were identified microscopically by the concentration of purple alkaline phosphatase reaction product within the cell cytoplasm, whereas sites of substance P and proneurotensin gene expression were identified by the dense clustering of silver grains overlying cells. An intense hybridization signal was detected for all three neuropeptide messenger RNAs in the striatum, the nucleus accumbens and septum. Dopamine and adenylate cyclase phosphoprotein-32 messenger RNA was detected within the neostriatum but not within the septum. In all forebrain regions examined, with the exception of the islands of Calleja, the cellular expression of enkephalin messenger RNA and substance P messenger RNA was discordant; the two neuropeptide messenger RNAs were detected essentially in different cells, although in the striatum and nucleus accumbens occasional isolated cells were detected which contained both hybridization signals; dense clusters of silver grains overlay alkaline phosphatase-positive cells, demonstrating clearly that these dual-labelled cells expressed both messenger RNAs. By contrast, the hybridization signals for proneurotensin and enkephalin, and proneurotensin and dopamine and adenylate cyclase phosphoprotein-32 were generally coincident, at least within the neostriatum; most proneurotensin messenger RNA-positive cells expressed enkephalin messenger RNA and were also positive for dopamine and adenylate cyclase phosphoprotein-32 messenger RNA. However, occasional proneurotensin messenger RNA-positive striatal cells were identified that were single-labelled and did not express enkephalin messenger RNA. Within the septal nucleus, enkephalin messenger RNA and substance P messenger RNA were expressed essentially within segregated cell populations. These studies illustrate further the utility of co-expression techniques for investigating the chemical phenotype of cells within the CNS and demonstrate that the distribution of neuropeptide co-expressing cells is different within different brain regions. That several populations of proneurotensin messenger RNA-positive striatal cells may exist, of which one population is sensitive to haloperidol, co-expresses enkephalin messenger RNA and is positive for dopamine and adenylate cyclase phosphoprotein-32 messenger RNA may be of some significance in neuropsychiatric/neurological disorders given that the translated peptide, neurotensin, is known to influence and interact closely with the dopamine systems.

Distribution of glucocorticoid receptor immunoreactivity and mRNA in the rat brain: an immunohistochemical and in situ hybridization study

The localization of glucocorticoid receptor (GR) immunoreactivity and mRNA in the adult rat brain was examined by light microscopic and electron microscopic immunohistochemistries, and in situ hybridization. For the purpose of detailed investigation of the distribution and comparison of GR immunoreactivities and mRNAs, specific polyclonal antibodies against a part of the transcription modulation (TR) domain of rat GR were used in the immunohistochemistry, whereas fluorescein-labeled RNA probes, complementary to the TR domain in the GR cDNA were used in the in situ hybridization. In the rat brain, GR immunoreactivity was predominantly localized in the cell nucleus, and the expression of GR mRNA was detected in the cytoplasm. GR-immunoreactive and GR mRNA-containing cells were widely distributed from the olfactory bulb of the forebrain to the gracile-cuneate nuclei of the medulla oblongata. The highest densities of GR-immunoreactive and mRNA-containing cells were observed in the subfields of cerebral cortex, olfactory cortex, hippocampal formation, amygdala, septal region, dorsal thalamus, hypothalamus, trapezoid body, cerebellar cortex, locus coeruleus and dorsal nucleus raphe. The distributional pattern of GR immunoreactivity in many regions was well-correlated with that of GR mRNA, but in the CA3 and CA4 pyramidal layers of the hippocampus, different localization was noted. The present study provides the groundwork for elucidating the role of GRs in brain function.

Morphological changes in met(5)-enkephalin-immunoreactive synaptic boutons in the rat neostriatum after haloperidol decanoate treatment

The morphological plasticity of an identified population of synaptic boutons in the rat neostriatum was investigated 24 h (short-term treatment) or 14 days (long-term treatment) after administration of the depot neuroleptic, haloperidol decanoate. Specific methionine(5)-enkephalin antiserum was used to label bouton profiles in the dorsal neostriatum. The size and shape of these boutons was subsequently analysed with quantitative methods at the ultrastructural level. Immunoreactive synaptic bouton profiles were found to have a larger cross-sectional area, to be less circular in shape and to have a longer maximum diameter after long-term neuroleptic treatment. These parameters were not significantly affected by short-term neuroleptic treatment. The morphological parameters indicate that methionine(5)-enkephalin-immunoreactive boutons become enlarged, probably by elongating. This suggests that boutons containing methionine(5)-enkephalin increase their potential synaptic efficacy in the long term after neuroleptic treatment.

Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion

Striatal mRNA expression for preproenkephalin (PPE) and preprotachykinin (PPT) was studied in unilateral 6-OHDA lesioned rats treated subchronically with a range of selective and non-selective D-1 or D-2 dopamine (DA) agonists. Apomorphine (5 mg/kg sc), pergolide (0.5 mg/kg sc), SKF 38393 (5 mg/kg sc), SKF 80723 (1.5 mg/kg sc), and quinpirole (5 mg/kg sc), or 0.9% saline (150 microliters sc) were all given twice daily (except pergolide: once daily) for 7 days. The abundance of PPE mRNA was not altered by any of these DA agonists in the intact striatum contralateral to the 6-OHDA lesion. Only apomorphine and quinpirole increased the abundance of PPT mRNA in the intact striatum. In saline treated 6-OHDA lesioned animals PPE mRNA was elevated (+160%, p < 0.005) and PPT mRNA decreased (-36%, p < 0.005) in the denervated striatum. The up-regulation of striatal PPE mRNA in the lesioned striatum was reversed only by pergolide. The downregulation of striatal PPT mRNA in the lesioned striatum was reversed only by apomorphine. The differential sensitivity of the striatal PPE message to the long-acting DA agonist pergolide, and of the striatal PPT message to the mixed D-1/D-2 DA agonist apomorphine suggests that the striatopallidal enkephalinergic pathways are mainly regulated by prolonged DA receptor stimulation, whereas the striatonigral substance P pathways are mainly regulated by mixed D-1/D-2 DA receptor stimulation.

Differential regulation of mRNA levels encoding for the two isoforms of glutamate decarboxylase (GAD65 and GAD67) by dopamine receptors in the rat striatum

The effects of in vivo administration of dopamine receptor agonists or antagonists on the mRNA levels encoding for the two isoforms of glutamate decarboxylase, GAD65 and GAD67, and for preproenkephalin were studied in regions of the rat dorsal striatum by radioactive in situ hybridization histochemistry. Changes in striatal mRNA levels after drug treatment were quantified by computerized densitometry on X-ray films. Chronic administration of the dopamine receptor agonist apomorphine or the D1 dopamine receptor agonist SKF-38393 resulted in increased GAD65 mRNA levels in the dorsomedial, ventromedial, dorsolateral and ventrolateral sectors of the striatum. Apomorphine or SKF-38393 treatment did not induce significant effects on GAD67 and preproenkephalin mRNA levels in striatum. On the other hand, chronic administration of the D2 dopamine receptor agonist quinpirole significantly decreased GAD67 in the dorsolateral and ventrolateral and preproenkephalin in the ventrolateral sectors of the striatum. Quinpirole treatment did not induce significant changes in GAD65 mRNA levels. Chronic administration of the dopamine receptor antagonist haloperidol resulted in a significant increase in GAD67 and preproenkephalin mRNA levels in the dorsomedial, dorsolateral and ventrolateral striatal sectors. Chronic treatment with the D2/D3 dopamine receptor antagonist sulpiride resulted in a significant increase in GAD67 in the ventromedial and ventrolateral and PPE in the dorsomedial and ventrolateral striatal sectors. Haloperidol or sulpiride did not induce significant changes in striatal GAD65 mRNA levels. Chronic administration of the D1 dopamine receptor antagonist SCH-23390 had no significant effect on GAD67, GAD65 or preproenkephalin mRNA levels. In the present experimental conditions, stimulation of dopamine receptors with apomorphine or SKF-38393 resulted in increased GAD65 mRNA levels whereas blockade of dopamine receptors with haloperidol or sulpiride resulted in increased GAD67 mRNA levels. These results indicate that striatal GAD65 and GAD67 mRNA levels are differentially regulated by dopamine receptor subtypes.

Acute and subchronic effects of dopamine agonists on neuropeptide gene expression in the rat striatum

Acute and subchronic (7 days) effects of subcutaneous administration of the D-1 agonist (SKF 38393; 5.0 mg/kg), the D-2 agonist (quinpirole; 5.0 mg/kg), the mixed D-1/D-2 agonist (apomorphine; 5.0 mg/kg) or pergolide (0.5 mg/kg) on enkephalin and substance P gene expression in the striatum were studied in rats using in situ hybridization. Striatal enkephalin mRNA levels were unaffected by acute dopamine agonist treatment despite animals exhibiting altered motor behaviour. Only acute apomorphine treatment increased substance P mRNA (25%, p < 0.01). Following subchronic administration of pergolide, enkephalin mRNA expression was decreased by 23% (p < 0.05) while other drugs were without effect. The abundance of striatal substance P mRNA was increased only following subchronic pergolide treatment (35%, p < 0.05). These data suggest that peptide gene expression in the intact striatum is relatively resistent to intermittent dopamine agonist stimulation in contrast to the pronounced alterations previously observed in 6-hydroxydopamine lesioned rats or following blockade of dopamine receptors.

Temporal changes in the messenger RNA levels of cellular immediate early genes and neurotransmitter/receptor genes in the rat neostriatum and substantia nigra after acute treatment with eticlopride, a dopamine D2 receptor antagonist

The cellular immediate early genes are involved in the transcriptional events associated with the dopaminergic regulation of neurotransmitter expression within neurons of the neostriatum. To characterize these events in detail, quantitative in situ hybridization histochemistry was used to assess the temporal effects of acute dopamine receptor blockade with eticlopride, a dopamine D2 receptor antagonist, on the messenger RNA expression of the immediate early genes and neurotransmitters/receptors in the caudate-putamen and ventral tegmental area/substantia nigra pars compacta of the rat. Groups of rats were injected with a single dose of either isotonic saline or eticlopride (0.5 mg/kg i.p.) and killed at various time intervals ranging from 5 min to 24 h and frozen brain sections processed by in situ hybridization histochemistry. Using computerized image analysis, the changes in messenger RNA expression for c-fos, c-jun, jun B, jun D, nerve growth factor I-A and nerve growth factor I-B and for neurotensin, glutamate decarboxylase, proenkephalin, the dopamine D1 receptor and the short and long isoforms of the D2 receptor were examined in the caudate-putamen. In the ventral tegmental area and substantia nigra pars compacta, the messenger RNA expression of the above early response genes and that for neurotensin, tyrosine hydroxylase, cholecystokinin and the D2 receptor isoforms were also examined. In the neostriatum, eticlopride caused a rapid increase in c-fos messenger RNA with significantly increased levels at 10 min (P < 0.01). The levels peaked at 30 min and thereafter declined to control levels. A similar profile was observed for jun B messenger RNA, although levels were still significantly (P < 0.01) elevated at 1 h and declined to basal levels thereafter. No significant changes were observed for c-jun, jun D, nerve growth factor I-A and nerve growth factor I-B messenger RNAs. In the dorsolateral neostriatum, there was an increase in proneurotensin messenger RNA 10 min after eticlopride, this increase becoming significant (P < 0.01) at 60 min. Levels were maximal at 2-6 h and decreased after 12 h to basal levels. There were small increases in proenkephalin messenger RNA, but these were not significant (P < 0.05) until 6 h after the injection. Eticlopride did not have any significant effects on the messenger RNA levels for glutamate decarboxylase, the D1 receptor and the short and long isoforms of the D2 receptor.(ABSTRACT TRUNCATED AT 400 WORDS)

Characterization and content of VIP and VIP mRNA in rat fore-brain neurones

HPLC, gel chromatography, Northern analysis and non-isotopic in situ hybridization have been used to characterize for the first time the nature of vasoactive intestinal polypeptide mRNA and peptide in the rat thalamus and suprachiasmatic nucleus. Both these hitherto unstudied areas were shown to contain VIP-like immunoreactivity and VIP mRNA indistinguishable from those found in the rat cerebral cortex. Non-isotopic in situ hybridization with an alkaline phosphatase labelled antisense oligonucleotide specific for VIP mRNA and densitometry revealed that relative levels of VIP mRNA per cell were highest in the suprachiasmatic nucleus and lowest per cell in the thalamus of the rat brain areas investigated.

Adenosine A2a receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a co-expression study

The cellular co-expression of adenosine A2a receptor mRNA and preproenkephalin A (PPE A) mRNA and A2a receptor mRNA and prosomatostatin (pSRIF) mRNA in rat striatum was studied using a combination of radioactive and non-radioactive in situ hybridization techniques. Cells containing adenosine A2a receptor mRNA were visualised using an 35S-labelled oligonucleotide whilst those containing PPE A mRNA and pSRIF mRNA were detected using alkaline phosphatase-labelled antisense oligonucleotides; both radioactive and non-radioactive hybridization signals were visualized on the same tissue section. Bright field examination of striatal sections hybridized with both the [35S]adenosine A2a receptor probe and the alkaline phosphatase-labelled PPE A probe revealed dense clusters of silver grains overlying cells containing alkaline phosphatase reaction product demonstrating that the two gene transcripts were expressed by the same medium-sized nerve cells. The cellular expression of the two mRNAs was consistently found to be concordant demonstrating that adenosine A2a receptor mRNA is expressed by medium-sized striatal enkephalin cells. In contrast, clusters of silver grains were never detected overlying striatal cells containing pSRIF mRNA indicating that this population of interneurones do not express the adenosine A2a receptor sub-type. The expression of adenosine A2a receptors by enkephalin cells in striatum suggests that adenosine may play a role in modulating the activity of GABA/enkephalin striatopallidal neurones through interaction with A2a receptors.

Co-expression of dopamine transporter mRNA and tyrosine hydroxylase mRNA in ventral mesencephalic neurones

Radioactive in situ hybridization was used to map the cellular localization of dopamine (DA) transporter mRNA-containing cells in the adult rat central nervous system. The distribution of DA transporter mRNA-containing cells was compared to adjacent sections processed to visualize tyrosine hydroxylase (TH) mRNA, a marker of catecholamine containing neurones. TH mRNA-containing cells, visualized using an alkaline phosphatase labelled probe, were detected in the hypothalamus, midbrain and pons; the strongest hybridization signals being detected in the substantia nigra, ventral tegmental area and locus coeruleus. The distribution of DA transporter mRNA-containing cells was more restricted; a strong signal being detected in the substantia nigra pars compacta and ventral tegmental area only. No hybridization signal was detected in the locus coeruleus. By simultaneously hybridizing mesencephalic tissue with both the alkaline phosphatase-labelled TH probe and the 35S-labelled DA transporter probe we were able to demonstrate that both DA transporter and TH mRNAs are expressed by the same cells in the substantia nigra and ventral tegmental area. The restricted anatomical localization of DA transporter mRNA-containing cells and the lack of expression in the locus coeruleus and other adrenergic and noradrenergic cell groups confirms the DA transporter as a presynaptic marker of DA containing nerve cells in the rat brain.

Time-course of changes in striatal levels of DA uptake sites, DA D2 receptor and preproenkephalin mRNAs after nigrostriatal dopaminergic denervation in the rat

Changes in striatal dopamine uptake sites, D2 receptor and preproenkephalin (PPE) mRNA levels provoked by unilateral 6-hydroxydopamine-induced lesion of the nigrostriatal dopaminergic (DA) pathway were studied by quantitative autoradiography and in situ hybridization (ISH) in rats sacrificed at different post-lesion delays. The disappearance of DA terminals as visualized with the labelling of dopamine uptake sites with [3H]GBR 12935 became significant 36 h after the lesion and was almost complete at a delay of 7 days. PPE mRNA amounts significantly increase (+24%) already at the shortest delay studied (9 h after the lesion) while the labelling of the uptake sites on DA terminals was not affected. The time course increase of PPE mRNA levels was progressive until 21 days post-lesion where it reached its maximum (+132%) and remained stable up to the latest delay studied (60 days). Conversely D2 mRNA contents remained unchanged up to 5 days post-surgery and then increased relatively quickly since at 7 days post-lesion their levels were near (+21%) the maximum observed which was reached at 21 days post-lesion (+32%). This study suggests a time-dependent differential sensitivity to the degree of DA denervation of both major components implicated in the striatopallidal output.

Dopamine decreases striatal enkephalin turnover and proenkephalin messenger RNA abundance via D2 receptor activation in primary striatal cell cultures

Dopaminergic regulation of striatal enkephalin biosynthesis and secretion was studied in primary neuronal cultures from fetal rat striatum. To allow pharmacological treatment, striatal primary cell cultures were seeded in chemically defined medium onto extracellular matrix. In these conditions, pharmacological treatment of the striatal neurons on the 10th day in vitro for 48 h with 10(-6) M dopamine induced a 50% decrease in preproenkephalin mRNA level concomitant with a 50% decrease in methionine enkephalin neuronal content. These effects of dopamine were mimicked by the D2 agonist bromocriptine (10(-6) M). The decrease in methionine enkephalin neuronal content induced by dopamine or bromocriptine was reversed by the simultaneous application of sulpiride (10(-6) M), a selective D2 antagonist. Interestingly, the D1 agonist SKF 38393 (10(-6) M) application for 24 or 48 h was found to have no significant effect on methionine enkephalin neuronal content. To ensure dopamine regulation of enkephalin secretion, shorter dopaminergic treatments were performed. Dopamine application (10(-6) M) for 2 h had no significant effect on basal methionine enkephalin secretion but significantly decreased (50%) methionine enkephalin secretion induced by KCl 56 mM. This effect of dopamine on the KCl-induced methionine enkephalin secretion was mimicked by bromocriptine (10(-6) M), reversed by sulpiride (10(-6) M) and unaffected by the D1 antagonist SCH 23390 (10(-6) M) application onto striatal neurons. Our data provide direct evidence for a dopaminergic inhibitory control on enkephalin biosynthesis and secretion from striatal cell cultures, mediated through the dopaminergic D2 receptor activation.

In-situ hybridization as a methodological tool for the neuroscientist

The technique of in-situ hybridization is now well established for the identification and localization of both DNA and mRNA in cells in the nervous system. For the nonspecialist neuroscientist, use of the technique has been greatly facilitated by the availability of convenient commercial kits for producing isotopically labelled cDNA and cRNA probes. Additionally, the development of synthetic oligonucleotide probes and nonradioactive detection for DNA or RNA has greatly contributed to accessibility of the technique.

Pertussis toxin administration increases the expression of proneurotensin and preproenkephalin A mRNAs in rat striatum

The effect of a unilateral intrastriatal microinjection of pertussis toxin on the expression of proneurotensin and preproenkephalin A mRNAs in the adult rat neostriatum was investigated using a technique of non-radioactive in situ hybridization. Control sham microinjected animals received an equal volume of vehicle only and were processed in parallel with the pertussis toxin-treated rats. All rats were allowed to recover from the stereotaxic surgery for 22 h before being killed and their brains rapidly removed and processed for in situ hybridization using alkaline phosphatase-labelled oligonucleotide probes. In comparison to sham microinjected rats, a single intrastriatal microinjection of pertussis toxin (1 microgram) resulted in a significant increase in the amount of both proneurotensin and preproenkephalin A mRNAs in the ipsilateral neostriatum. For proneurotensin mRNA, this increase was reflected by a substantial increase in the number of mRNA-containing cells detected. Proneurotensin mRNA-containing cells detected in the nucleus accumbens appeared to be unaffected by the intrastriatal pertussis toxin microinjection. In contrast, the significant increase in preproenkephalin A mRNA, when compared to the contralateral uninjected striatum and the ipsilateral striatum of control sham injected rats, was reflected by an increase in the cellular amount of preproenkephalin A mRNA and not by an increase in the number of mRNA-containing cells detected. These results demonstrate that the expression of both proneurotensin mRNA and preproenkephalin A mRNA in the adult rat striatum are rapidly increased in vivo by an intrastriatal microinjection of pertussis toxin.